Form 4: ADMA Director Salas Increases Stake with Equity Grants

ADMA Biologics Director Eduardo Rene Salas received grants of 10,690 restricted stock units and 17,730 stock options, aligning his interests with shareholders.

Summary

• Director Eduardo Rene Salas of ADMA Biologics, Inc. was granted 10,690 restricted stock units (RSUs) on February 9, 2026.
• These RSUs will vest in two equal installments on the sixand 12-month anniversaries of the grant date, becoming fully vested on February 9, 2027, contingent on continued service.
• Salas also received a grant of 17,730 stock options on February 9, 2026, with an exercise price of $16.37 per share.
• These stock options will vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the grant date, and have an expiration date of February 9, 2036.
• Following these transactions, Salas beneficially owns 21,579 shares of common stock, which includes the newly granted 10,690 RSUs, 5,445 previously granted RSUs vesting on February 19, 2026, and 5,444 shares of common stock.
• He also beneficially owns 17,730 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, indicating management's continued commitment and alignment with shareholder interests through equity compensation, which is generally well-received by the market.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs (fully vested on 1-year anniversary) and stock options (fully vested on 1-year anniversary) encourage continued service and commitment from the director.
• The increase in beneficial ownership by a director signals confidence in the company's future prospects.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, serving to align leadership incentives with long-term shareholder value creation. This particular grant to a director at ADMA Biologics reflects a common compensation strategy aimed at retaining key talent and fostering commitment within a competitive sector.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value creation.
• Employees: Standard equity compensation practices can positively influence employee morale and retention by demonstrating a commitment to rewarding leadership.

Next Steps

• Vesting of 5,445 RSUs on February 19, 2026.
• Vesting of 10,690 RSUs in two equal installments, fully vesting on February 9, 2027.
• Vesting of 17,730 stock options in twelve equal monthly installments, fully vesting on February 9, 2027.
• Potential exercise of 17,730 stock options before their expiration on February 9, 2036.

Key Dates

Recommendation

The grant of equity to a director is a positive indicator of insider confidence and alignment with long-term company performance. While not a standalone catalyst for a 'buy' recommendation, it reinforces a 'hold' position by suggesting management believes in the company's future prospects.

Keywords

ADMA Biologics, ADMA, Eduardo Rene Salas, Director, Restricted Stock Units, RSUs, Stock Options, Insider Transaction, Beneficial Ownership, Equity Compensation, Corporate Governance